Bristol Myers Q3 Beat Fails to Shift Our Stock Caution

Bristol Myers just posted a solid Q3 beat and hiked full-year sales guidance to $47.5B-$48B. Shares jumped 6%, but we...

30/10/2025

2 views

Trimming Bristol Myers Position After Earnings Surge

Shares of this major drugmaker jumped over 4% on a solid earnings beat and raised guidance. But we're selling 300...

30/10/2025

5 views

Why did the stock rally fizzle out? Dive into the latest on Goldman Sachs and Bristol Myers, and what it...

29/05/2025

0 views

Tesla and Enphase tank after earnings misses, while Oklo faces leadership shifts. What’s driving these after-hours moves? Click to find...

22/04/2025

1 views